Gastric Cancer (GC)
Oncology·MeSH: Sarcoglycanopathies
Prevalence
10.0 / 100K
Incidence
6.1 / 100K/yr
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| sugemalimab | EQRx, Inc. (EQRX) |
Frequently asked questions
How many drugs are in development for Gastric Cancer (GC)?
BioSniper tracks 1 drug in development for Gastric Cancer (GC) across 1 company.
How many clinical trials target Gastric Cancer (GC)?
There are 4 clinical trials targeting Gastric Cancer (GC) tracked by BioSniper.
What is the prevalence of Gastric Cancer (GC)?
The estimated prevalence of Gastric Cancer (GC) is approximately 10.0 per 100,000 population.
Deep-dive into Gastric Cancer (GC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis